JP2023538144A5 - - Google Patents
Info
- Publication number
- JP2023538144A5 JP2023538144A5 JP2023512783A JP2023512783A JP2023538144A5 JP 2023538144 A5 JP2023538144 A5 JP 2023538144A5 JP 2023512783 A JP2023512783 A JP 2023512783A JP 2023512783 A JP2023512783 A JP 2023512783A JP 2023538144 A5 JP2023538144 A5 JP 2023538144A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- group
- alkyl
- ionizable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068944P | 2020-08-21 | 2020-08-21 | |
| US63/068,944 | 2020-08-21 | ||
| PCT/US2021/047203 WO2022040641A2 (en) | 2020-08-21 | 2021-08-23 | Functional ionizable phospholipids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538144A JP2023538144A (ja) | 2023-09-06 |
| JP2023538144A5 true JP2023538144A5 (https=) | 2024-11-05 |
| JP7849049B2 JP7849049B2 (ja) | 2026-04-21 |
Family
ID=80323210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512783A Active JP7849049B2 (ja) | 2020-08-21 | 2021-08-23 | 機能性のイオン化可能なリン脂質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230320994A1 (https=) |
| EP (1) | EP4199934A4 (https=) |
| JP (1) | JP7849049B2 (https=) |
| CN (1) | CN117355335A (https=) |
| AU (1) | AU2021327782A1 (https=) |
| CA (1) | CA3189905A1 (https=) |
| WO (1) | WO2022040641A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024511463A (ja) * | 2021-03-22 | 2024-03-13 | リコード セラピューティクス，インク． | 細胞への標的送達のための組成物および方法 |
| CA3213107A1 (en) | 2021-03-23 | 2022-09-29 | Mirko HENNIG | Polynucleotide compositions, related formulations, and methods of use thereof |
| WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
| EP4385523A1 (en) * | 2022-12-14 | 2024-06-19 | Beijing Jitai Pharmaceutical Technology Co., Ltd. | Lipid-based topical injection formulations |
| CN116211831A (zh) * | 2022-12-14 | 2023-06-06 | 北京剂泰医药科技有限公司 | 脂质基质局部注射制剂 |
| AU2023407378A1 (en) * | 2022-12-23 | 2025-07-03 | Turn Biotechnologies, Inc. | Dual lipid structures |
| AU2024236558A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| AU2024234874A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| CN119997938A (zh) * | 2023-06-05 | 2025-05-13 | 安徽医科大学第一附属医院 | 肺靶向纳米胶束、制备方法及应用 |
| CN117180196B (zh) * | 2023-08-09 | 2025-11-18 | 福建师范大学 | 一种抗原适配型的疫苗佐剂体系及其在制备新冠和猴痘疫苗中的应用 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| WO2025166238A1 (en) | 2024-01-31 | 2025-08-07 | Orna Therapeutics, Inc. | Fast-shedding polyethylene glycol lipids |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4774350A (en) * | 1985-08-30 | 1988-09-27 | Kao Corporation | Phosphoric ester |
| DE4111105A1 (de) * | 1991-04-05 | 1992-10-08 | Max Planck Gesellschaft | Neue erucyl-, brassidyl- und nervonylderivate |
| JPH06157560A (ja) * | 1992-11-26 | 1994-06-03 | Toyo Ink Mfg Co Ltd | リン脂質系界面活性剤及びその製造方法 |
| AU9263298A (en) | 1997-08-18 | 1999-03-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Phospholipid analogue compounds |
| WO2003062290A1 (en) * | 2002-01-16 | 2003-07-31 | Biocompatibles Uk Limited | Polymer conjugates |
| DE10207178A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Komponenten für die Herstellung amphoterer Liposomen |
| UA99434C2 (ru) * | 2005-12-19 | 2012-08-27 | Аетерна Центаріс Гмбх | Применение производных алкилфосфолипидов со сниженной цитотоксичностью |
| DE102006028983A1 (de) | 2006-06-23 | 2007-12-27 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Phosphorsäurediesteramide |
| JP5488121B2 (ja) | 2010-03-31 | 2014-05-14 | 日油株式会社 | 経皮吸収促進及び／又は保湿性向上作用を示す剤、並びに化粧料 |
| FR2966727B1 (fr) * | 2010-11-03 | 2013-04-12 | Oreal | Utilisation comme antipelliculaire de polymeres phospholipidiques |
| FR2990206B1 (fr) * | 2012-05-07 | 2014-06-06 | Commissariat Energie Atomique | Nouveaux composes bifonctionnels utiles comme ligands de l'uranium(vi), leurs procedes de synthese et leurs utilisations |
| US12415939B2 (en) * | 2015-09-30 | 2025-09-16 | The Regents Of The University Of California | Nano-adhesive and surface primer compound and use thereof |
| PL3386484T3 (pl) * | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| CN109414408B (zh) | 2016-05-16 | 2022-03-29 | 得克萨斯州大学系统董事会 | 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质 |
-
2021
- 2021-08-23 JP JP2023512783A patent/JP7849049B2/ja active Active
- 2021-08-23 AU AU2021327782A patent/AU2021327782A1/en active Pending
- 2021-08-23 CN CN202180069932.XA patent/CN117355335A/zh active Pending
- 2021-08-23 EP EP21859283.0A patent/EP4199934A4/en active Pending
- 2021-08-23 CA CA3189905A patent/CA3189905A1/en active Pending
- 2021-08-23 US US18/042,390 patent/US20230320994A1/en active Pending
- 2021-08-23 WO PCT/US2021/047203 patent/WO2022040641A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538144A5 (https=) | ||
| Xiao et al. | Emerging mRNA technologies: delivery strategies and biomedical applications | |
| Kazemian et al. | Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components | |
| JP7849049B2 (ja) | 機能性のイオン化可能なリン脂質 | |
| Li et al. | Nanoscale platforms for messenger RNA delivery | |
| Huang et al. | The roles of polymers in mRNA delivery | |
| Kumar et al. | Polymeric delivery of therapeutic nucleic acids | |
| Navarro et al. | Micelle-like nanoparticles as carriers for DNA and siRNA | |
| Moss et al. | Lipid nanoparticles for delivery of therapeutic RNA oligonucleotides | |
| Tang et al. | Ionizable lipid nanoparticles for mRNA delivery | |
| Guan et al. | Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems | |
| Lin et al. | Targeting materials and strategies for RNA delivery | |
| Romberg et al. | Sheddable coatings for long-circulating nanoparticles | |
| Kim et al. | Efficient gene delivery by urocanic acid-modified chitosan | |
| Hatakeyama et al. | A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo | |
| Zhang et al. | Cationic compounds used in lipoplexes and polyplexes for gene delivery | |
| Draghici et al. | Synthetic nucleic acid delivery systems: present and perspectives | |
| Yang et al. | Design, preparation and application of nucleic acid delivery carriers | |
| Yuan et al. | Recent advances of siRNA delivery by nanoparticles | |
| KR102285326B1 (ko) | Rna를 세포에 도입하기 위한 조성물 | |
| Dutta et al. | Disulfide bridging strategies in viral and nonviral platforms for nucleic acid delivery | |
| Jones et al. | Hydrophobically modified dendrons: developing structure− activity relationships for DNA binding and gene transfection | |
| Rouatbi et al. | Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview | |
| Tschiche et al. | Nonviral gene delivery with dendritic self-assembling architectures | |
| Wang et al. | Recent progress in nucleic acid pulmonary delivery toward overcoming physiological barriers and improving transfection efficiency |